课题基金 / 基金详情

Elucidating the Inhibitory Mechanisms of RNA Triple Helices in Nuclear Decay

Elucidating the Inhibitory Mechanisms of RNA Triple Helices in Nuclear Decay
阐明 RNA 三螺旋在核衰变中的抑制机制
批准号:
9535374
负责人:
JESSICA Ann BROWN
金额:
$24.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2019-07-31

项目摘要

项目成果

JESSICA Ann BROWN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):多腺苷化核糖核酸(PAN)RNA是由卡波西肉瘤相关疱疹病毒产生的最丰富的裂解相转录本。它的高核聚集性定位于一个表达和核保持元件(ENE)。PAN ENE的富含U的内环将PAN RNA的32-聚(A)尾巴隔离成一个三螺旋(记为ENE+A),从而保护转录本免受一种新的依赖于死烯基化的核RNA衰退途径的影响。两个细胞长非编码RNA(LncRNAs)的32端序列形成了相似的ENE结构:转移相关肺腺癌转录本1(MALAT1)和多发性内分泌肿瘤β(MENS?)。这些lncRNAs在癌细胞中含量很高,尽管缺乏典型的PolyA尾巴。相反,32个基因组编码的富含A的区域被MALAT1和MENS的烯隔离成建议的钝端三链。由于3‘-GT;5’腐烂通常是由与单链RNA结合的核酸外切酶启动的,因此细胞Enes+A的钝端可能经历了与病毒Enes+A的32-Poly(A)尾部不同的衰变过程。此外,假定的细胞Enes+A的三联体包含被G和C核苷酸打断的UA-U三联体,这在所有病毒Ens中都不存在。我假设不同的病毒和细胞内的ENE+A结构是通过不同的衰变机制降解的。病毒和细胞内ENE+A结构如何不同地阻止核RNA衰变的分子基础尚未被研究。PAN RNA和MALAT1的快速核RNA衰退途径的酶组分尚不清楚,但PAN RNA可能被Poly(A)特异性核糖核酸酶(Parn)去烯化。在目标1中,一系列基于细胞的分析将表征核RNA衰变中的MALAT1 ENE+A,包括时间分辨32-RACE和基于RNA的击倒方法来识别衰变机制。在目标2中,动力学分析将为病毒和细胞enes+A如何在结合和核苷酸切除步骤中抑制衰变酶建立机制基础。在目标3中,X射线结晶学将被用来解决衰变酶与PAN或MALAT1 ENE+A形成的络合物的结构。解决这些结构将为酶如何识别并与三链相互作用提供第一个洞察力。初步的动力学和结构研究将使用PAN和PAN ENE+A作为模型体系。类似的分析将对目标1中发现的MALAT1 ENE+A及其衰变机制进行。这些实验将阐明三螺旋RNA稳定元件如何阻止核RNA衰变的分子机制,同时对核LncRNA衰变的未被研究的途径、RNA三联体的生物学作用以及稳定MALAT1(一种促癌的lncRNA)的机制提供重要的见解。这一职业发展奖将使我能够在耶鲁大学的Joan Steitz博士和Thomas Steitz博士的实验室中发展我的专业技能(如课堂教学)并获得特定的技术培训(如X射线结晶学)。这些活动将使我能够获得学术教授的职位,并建立一个顶级的研究小组。
英文摘要
DESCRIPTION (provided by applicant): Polyadenylated nuclear (PAN) RNA is the most abundant lytic-phase transcript produced by the Kaposi's sarcoma-associated herpesvirus. Its high nuclear accumulation localizes to an expression and nuclear retention element (ENE). The U-rich internal loop of the PAN ENE sequesters the 32-poly(A) tail of PAN RNA into a triple helix (denoted as ENE+A) that protects the transcript from a novel rapid deadenylation-dependent nuclear RNA decay pathway. Similar ENE structures are formed by the 32-end sequences of two cellular long noncoding RNAs (lncRNAs): metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and multiple endocrine neoplasia beta (MENß). These lncRNAs are highly abundant in cancer cells despite lacking canonical poly(A) tails. Instead, 32-genomically-encoded A-rich tracts are sequestered by the ENEs of MALAT1 and MENß RNAs into proposed blunt-ended, triplexes. Because 3'->5' decay is typically initiated by an exonuclease binding to single-stranded RNA, the blunt-ends of cellular ENEs+A are likely subjected to different decay processes than the 32-poly(A) tails of viral ENEs+A. Moreover, the putative triplexes of cellular ENEs+A contain UA-U triples interrupted by G and C nucleotides that are absent in all viral ENEs. I hypothesize that the different viral and cellular ENE+A structures are degraded via distinct decay mechanisms. The molecular basis for how viral and cellular ENE+A structures differentially block nuclear RNA decay has not been investigated. The enzymatic components of the rapid nuclear RNA decay pathway are unknown for PAN RNA and MALAT1 except that PAN RNA is likely deadenylated by poly(A)-specific ribonuclease (PARN). In Aim 1, a series of cell-based assays will characterize the MALAT1 ENE+A in nuclear RNA decay, including time-resolved 32-RACE and RNA-based knockdown approaches to identify decay machinery. In Aim 2, kinetic assays will establish the mechanistic basis for how viral and cellular ENEs+A inhibit decay enzymes during the binding and nucleotide excision steps. In Aim 3, X-ray crystallography will be used to solve the structures of decay enzymes in complex with the PAN or MALAT1 ENE+A. Solving these structures will provide the first insights into how enzymes recognize and interact with triplexes. Initial kinetic and structural studies will use PARN and PAN ENE+A as a model system. Similar analyses will be performed with the MALAT1 ENE+A and its decay machinery uncovered in Aim 1. These experiments will elucidate the molecular mechanisms of how triple-helical RNA stabilization elements impede nuclear RNA decay while providing significant insights into the understudied pathways of nuclear lncRNA decay, the biological roles of RNA triplexes, and the mechanisms that stabilize MALAT1, a cancer-promoting lncRNA. This Career Development Award will allow me to develop my professional skills (e.g. classroom teaching) and to acquire specific technical training (e.g. X-ray crystallography) in the laboratories of Drs. Joan Steitz and Thomas Steitz at Yale University. These activities will enable me to secure an academic professorship and to build a top-tier research group.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Structural basis of methotrexate and pemetrexed action on serine hydroxymethyltransferases revealed using plant models.
使用植物模型揭示甲氨蝶呤和培美曲塞对丝氨酸羟甲基转移酶作用的结构基础。
DOI: 10.1038/s41598-019-56043-4
发表时间: 2019
期刊: Scientific reports
影响因子: 4.6
作者: [Ruszkowski,Milosz, Sekula,Bartosz, Ruszkowska,Agnieszka, Contestabile,Roberto, Nogues,Isabel, Angelaccio,Sebastiana, Szczepaniak,Andrzej, Dauter,Zbigniew]
通讯作者: Dauter,Zbigniew
DOI: 10.1021/acs.biochem.2c00601
发表时间: 2023-01-17
期刊: BIOCHEMISTRY
影响因子: 2.9
作者: [Breger, Kurtis, Brown, Jessica A.]
通讯作者: Brown, Jessica A.
DOI: 10.3389/fpls.2018.00584
发表时间: 2018
期刊: Frontiers in plant science
影响因子: 5.6
作者: [Ruszkowski M, Sekula B, Ruszkowska A, Dauter Z]
通讯作者: Dauter Z
Characterization of a Model System to Advance Triple-Stranded RNA Biology
  • 批准号:
    10669618
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2019
  • 负责人:
    JESSICA Ann BROWN
  • 依托单位:
Characterization of a Model System to Advance Triple-Stranded RNA Biology
  • 批准号:
    10457927
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2019
  • 负责人:
    JESSICA Ann BROWN
  • 依托单位:
Characterization of a Model System to Advance Triple-Stranded RNA Biology
  • 批准号:
    10210410
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2019
  • 负责人:
    JESSICA Ann BROWN
  • 依托单位:
Characterization of a Model System to Advance Triple-Stranded RNA Biology
  • 批准号:
    9797666
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2019
  • 负责人:
    JESSICA Ann BROWN
  • 依托单位:
海外基金